Double Helix Venture Fund

We focus on creating value in high-growth markets by driving innovation across the Healthtech and Life Sciences ecosystem

Cross-cutting principles
  • Evidence-led: we fund milestones, not narratives.
  • Regulatory clarity: credible CE/FDA/MDR/IVDR and GxP plans.
  • Economic value: quantified impact on outcomes, cost or productivity.
  • Defensibility: IP, data flywheels and ecosystem integrations.
  • Go-to-market realism: defined ICP, sales cycle insight, integration prerequisites.
Contact us
Diagnostics, Preventive & Precision Health

Health Data, Software & AI Infrastructure

Life Sciences Tools, Automation & Industrialization

Longevity, Wellness & Personalized Health

Diagnostics, Preventive & Precision Health

From early detection to precision monitoring and risk stratification across clinical and consumer contexts.

Who buys: Providers, Lab, Payers, Pharma (CDx), Employers
 
What we back:
  • IVD/POC, biomarkers, liquid biopsy, imaging-enabled diagnostics.
  • Remote monitoring, digital biomarkers, triage and risk scoring.
  • Companion diagnostics, pharmacogenomics, precision prevention.
Investment criteria:
  • Demonstrable clinical utility and cost impact.
  • Clear regulatory path (IVDR/CE, FDA) and reimbursement lane.
  • Evidence plan underway (validation, KOL engagement).

Health Data, Software & AI Infrastructure

Systems that unlock measurable clinical and economic value across the healthcare stack.

Who buys: Providers • Payers • Labs • Health systems • Life sciences.

What we back:
  • Clinical decision support, workflow automation, EHR/LIS/LIMS integrations.
  • Interoperability, RWE/data platforms, privacy-preserving analytics.
  • Payer solutions: reimbursement intelligence, utilization management, RCM
    Vertical AI and foundation models with proprietary datasets
Investment criteria:
  • Validated outcome or cost improvements; clear ROI for buyer.
  • Secure data governance (HIPAA/GDPR), explainability where required.
  • Repeatable sales motion with defined ICP and integration path.

Life Sciences Tools, Automation & Industrialization

Enabling platforms accelerating discovery, development, and scaled manufacturing in biotech and pharma.

Who buys: Biotech • Pharma • CROs/CMOs • Advanced labs

What we back:

  • Lab automation, robotics, imaging, fluidics, single-cell/omics instrumentation.
  • Assay development, sample prep, QC/QA, bioprocess monitoring/control.
  • LIMS/MES/ELN software, digital twins, process simulation.
  • GMP scale-up, continuous manufacturing, tech transfer enablers.
Investment criteria:
  • Tangible gains (throughput, accuracy, cost) and clear ROI.
  • Regulatory/GxP readiness and serviceability at scale.
  • Defensible IP and expansion roadmap (modules, consumables, software).

Longevity, Wellness & Personalized Health

Evidence-based products and platforms advancing healthy lifespan and performance.

Who buys: Consumers (selectively) • Providers • Employers • Payers • Sports & rehab.
What we back:
  • Omics-driven personalization (genomics, proteomics, metabolomics, microbiome).
  • Metabolic, musculoskeletal, cognitive and sleep optimization.
  • Healthy aging, sarcopenia, fall prevention, rehabilitation and recovery tech.
  • Consumer-to-clinic bridges with measurable outcomes.

Investment criteria:

  • Measurable health outcomes and defensible data moats.
  • Clear channel strategy (B2B/B2B2C/employer/payer) and unit economics.
  • Compliance-by-design for data privacy and claims.

Become part of a thriving community of investors and innovators committed to transforming healthcare through strategic investments.

Contact us